Ampio Pharm
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Ampio Pharm (AMPE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: -0.687x
Based on the latest financial reports, Ampio Pharm (AMPE) has a cash flow conversion efficiency ratio of -0.687x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.31 Million) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ampio Pharm - Cash Flow Conversion Efficiency Trend (2006–2023)
This chart illustrates how Ampio Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ampio Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ampio Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
True Games Syndicate S.A.
WAR:TGS
|
N/A |
|
B F Modaraba
KAR:BFMOD
|
N/A |
|
Jetwing Symphony Ltd
CM:JETSN0000
|
N/A |
|
Sakrand Sugar Mills Ltd
KAR:SKRS
|
N/A |
|
Foothills S.A.
WAR:FTL
|
N/A |
|
Advanced Container Technologies Inc
PINK:ACTX
|
0.041x |
|
Alumex PLC
CM:ALUMN0000
|
N/A |
|
Adhera Therapeutics Inc
PINK:ATRX
|
0.001x |
Annual Cash Flow Conversion Efficiency for Ampio Pharm (2006–2023)
The table below shows the annual cash flow conversion efficiency of Ampio Pharm from 2006 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.36 Million | $-8.56 Million | -2.549x | -42.22% |
| 2022-12-31 | $11.79 Million | $-21.13 Million | -1.792x | -247.06% |
| 2021-12-31 | $27.28 Million | $-14.09 Million | -0.516x | +38.60% |
| 2020-12-31 | $17.51 Million | $-14.73 Million | -0.841x | +64.77% |
| 2019-12-31 | $6.44 Million | $-15.38 Million | -2.388x | -2.99% |
| 2018-12-31 | $5.24 Million | $-12.14 Million | -2.318x | -794.49% |
| 2017-12-31 | $-34.18 Million | $-11.41 Million | 0.334x | +115.14% |
| 2016-12-31 | $6.63 Million | $-14.62 Million | -2.204x | -216.17% |
| 2015-12-31 | $37.93 Million | $-26.44 Million | -0.697x | -48.47% |
| 2014-12-31 | $65.46 Million | $-30.74 Million | -0.470x | +18.47% |
| 2013-12-31 | $33.21 Million | $-19.13 Million | -0.576x | -41.30% |
| 2012-12-31 | $23.83 Million | $-9.72 Million | -0.408x | +20.71% |
| 2011-12-31 | $17.76 Million | $-9.13 Million | -0.514x | -178.42% |
| 2010-12-31 | $-4.01 Million | $-2.63 Million | 0.656x | +114.42% |
| 2009-12-31 | $-69.92K | $-21.38K | 0.306x | -64.49% |
| 2008-12-31 | $-43.86K | $-37.77K | 0.861x | -43.75% |
| 2007-12-31 | $-11.98K | $-18.35K | 1.531x | +3194.79% |
| 2006-12-31 | $20.01K | $-990.00 | -0.049x | -- |